Fasudil for ovarian cancer with A/A gene type
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if adding fasudil hydrochloride to your current chemotherapy can help when ovarian cancer has stopped responding to platinum-based chemo. It is for people whose tumor has a specific gene pattern called A/A.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ovarian cancer that stayed the same or got worse after two rounds of platinum chemotherapy.
- A genetic test must show you have the A/A genotype.
- You are willing to take fasudil along with your current chemo regimen.
- You do not have low blood pressure, active bleeding in the brain, or abnormal liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two investigational drug combinations (fluzoparib plus famitinib, or fluzoparib plus SHR-1701) given before surgery to shrink ovarian cancer. The goal is to see which approach helps more with tumor reduction and making surgery more effective.
This trial is testing a new drug (SHR-A1811) versus standard chemotherapy for women with platinum-resistant ovarian cancer. The study looks at a specific protein (HER2) to see if the new treatment can help slow or stop the cancer.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
This study tests a new combination of two investigational drugs for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a BRCA gene mutation. The goal is to see if the combination is safe and effective, and it might offer a new treatment option for your type of cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.